Compare KSCP & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | EVAX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9M | 29.7M |
| IPO Year | 2022 | 2020 |
| Metric | KSCP | EVAX |
|---|---|---|
| Price | $1.23 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.00 | $11.67 |
| AVG Volume (30 Days) | ★ 603.6K | 229.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,335,000.00 | N/A |
| Revenue This Year | $218.66 | N/A |
| Revenue Next Year | $54.32 | $328.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.91 | N/A |
| 52 Week Low | $1.32 | $2.77 |
| 52 Week High | $7.62 | $12.15 |
| Indicator | KSCP | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 46.68 |
| Support Level | N/A | $3.02 |
| Resistance Level | $1.52 | $3.62 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 10.26 | 31.84 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.